Neupogen
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
slow white blood cell recovery following chemotherapy
General Information
Neupogen has been approved for its fifth indication: to reduce
the time to neutrophil recovery and the duration of fever following
chemotherapy treatment in patients being treated for acute
myeologenous leukemia. Patients with this type of leukemia can now
receive Neupogen to improve their ability to tolerate essential
chemotherapy treatments.
